Crossmark

Predicting health-related quality of life two years post-diagnosis across seven cancer types: using machine learning to identify vulnerable patients

Crossref DOI link: https://doi.org/10.1007/s11136-026-04165-4

Published Online: 2026-02-12

Published Print: 2026-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Oudijk, Willemijn F. https://orcid.org/0009-0000-0801-8262
de Rooij, Belle H. https://orcid.org/0000-0002-0172-0857
van Benthem, Koen J. https://orcid.org/0000-0002-3841-2110
Etienne, Rampal S. https://orcid.org/0000-0003-2142-7612
Oerlemans, Simone https://orcid.org/0000-0003-1595-7262
Verkooijen, Helena M. https://orcid.org/0000-0001-9480-1623
Aben, Katja K. H. https://orcid.org/0000-0002-0214-2147
Vink, Geraldine R. https://orcid.org/0000-0002-6731-9660
May, Anne M. https://orcid.org/0000-0003-0643-3790
Mols, Floortje https://orcid.org/0000-0003-0818-2913
Katsimpokis, Dimitris https://orcid.org/0000-0002-4073-0206
Ezendam, Nicole P. M. https://orcid.org/0000-0002-5878-4210
Funding

Funding for this research was provided by:

KWF Kankerbestrijding (UVT 2010-4743)

KWF Kankerbestrijding (UVA 2013-6331)

KWF Kankerbestrijding (2013-5942)

KWF Kankerbestrijding (2015–7914)

Netherlands Organization for Scientific Research (2016/04981/ZONMW-91101002)

Center of Research on Psychological disorders and Somatic diseases

the Netherlands Comprehensive Cancer Organisation

Stand Up To Cancer

ZonMw

Health~Holland

Maag Lever Darm Stichting

Merck

Bristol-Myers Squibb

Bayer

Servier

Department of Radiation Oncology of the University Medical Center Utrecht

Julius Center for Health Sciences and Primary Care of the University Medical Center Utrecht
License Information

Text and Data Mining valid from 2026-02-12

Version of Record valid from 2026-02-12
More Information

Article History

Received: 26 February 2025

Accepted: 26 September 2025

First Online: 12 February 2026

Declarations

:

: GV obtained research grants to institution: Bayer, BMS, Delfi Diagnostics, Merck, Natera, Nordic pharma, Labcorp (Personal Genome Diagnostics), Pierre Fabre, Servier, Sirtex.

: Ethical approval was previously obtained for each study cohort separately (ROGY: NL33429.008.10 [ ]; PROCORE: NL51119.060.14 [ ]; PLCRC: NL47888.041.14 [ ]; UMBRELLA: NL52062.041.15 [ ]). Both the BlaZIB [ ] and ProZIB [ ] studies were beyond the scope of the Medical Research Involving Human Subjects Act (WMO) and, therefore, an ethics approval was waived.

: Informed consent was obtained from all individual participants included in the study.

: Not applicable.

Document is current

Any future updates will be listed below